Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA ® (finerenone), which ...
Bayer recently announced that the U.S. FDA has granted Priority Review to HYRNUO (sevabertinib) as a first-line treatment for ...
BAYRY wins FDA priority review for sevabertinib in first-line HER2-mutant NSCLC, building momentum for the oral TKI.
US FDA grants priority review status to Bayer’s sevabertinib for first-line treatment for patients with HER2-mutant non-small cell lung cancer: Berlin Wednesday, May 20, 2026, 1 ...
A new agreement between Bayer Vietnam and the NHOG aims to broaden women's access to advanced medical treatments.
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
Bayer and Cleopatra Hospitals Group have signed a Memorandum of Understanding aimed at strengthening cooperation between the ...
The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they ...
Chelsea have accelerated their efforts to appoint Xabi Alonso as the club's next permanent head coach. The Stamford Bridge ...
Bayer AG and Perfuse Therapeutics Inc. have announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, ...
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results